EDIT Editas Medicine Inc

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

Citi’s 15th Annual BioPharma Virtual ConferencePanel: Innovation in Cell TherapyDate: Wednesday, September 9, 2020Time: 3:20 p.m. ET

Wells Fargo 2020 Virtual Healthcare Conference Fireside ChatDate: Thursday, September 10, 2020Time: 10:40 a.m. ET

Morgan Stanley 18th Annual Global Healthcare ConferenceFireside ChatDate: Tuesday, September 15, 2020Time: 10:15 a.m. ET

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor ContactMark Mullikin(617) 401-9083mark.mullikin@editasmed.com

Media ContactCristi Barnett(617) 401-0113cristi.barnett@editasmed.com